Skip to content


    DEA Class; OTC

    Common Brand Names; Carafate

    • Gastrointestinal Agents, Other

    Oral aluminum-containing sucrose sulfate complex; forms adherent, protective barrier at sites of damaged GI mucosa, shields mucosa from pepsin, acid, and bile; used for esophagitis, GERD, GI ulceration, and stomatitis.

    Indicated for the treatment of duodenal ulcer not related to NSAID use.

    Treatment of oral ulcerations and dysphagia in patients with epidermolysis bullosa

    Treatment of oral complications of chemotherapy in bone marrow transplant recipients

    For the treatment of gastric ulcer not related to NSAID use or for treatment of esophagitis associated with gastroesophageal reflux disease (GERD).

    Documented hypersensitivity

    • Constipation (2%)
    • Diarrhea
    • Dizziness
    • Dry mouth
    • Flatulence
    • Headache
    • Indigestion
    • Insomnia
    • Nausea
    • Vertigo
    • Vomiting

    Not expected to alter post healing frequency of recurrence or severity of duodenal ulceration; acts locally at the ulcer

    Do not take antacids within 30 minutes of sucralfate dose

    Aluminum absorption is increased; use with caution in patients with chronic renal failure or undergoing dialysis

    Potential significant drug interactions possible; consult drug interaction database

    Use tablet with caution in patients with conditions that may impair swallowing, or with altered gag/cough reflex

    Hyperglycemia has been reported when drug is used in patients with diabetes

    Sucralfate may alter absorption of some drugs; take other medications 2 hours before taking sucralfate

    Fatal complications, including pulmonary and cerebral emboli reported with inappropriate intravenous administration of oral suspension; administer oral suspension only by oral route; not for intravenous administration

    Pregnancy category: B

    Lactation: Probably safe because drug is minimally absorbed; unknown whether drug is excreted in breast milk


    4 g/day PO.


    4 g/day PO.


    4 g/day PO.


    Maximum dosage not established. 80 mg/kg/day PO or alternatively, up to 2000 mg/day PO has been suggested for most indications.



    • 1g

    oral suspension

    • 1000mg/10mL